Septic shock continues to pose a formidable challenge in intensive care units worldwide, representing a leading cause of mortality among critically ill patients, particularly those suffering from acute kidney injury requiring continuous renal replacement therapy (CRRT). Despite substantial advances in critical care practices, the grim reality remains: mortality rates are distressingly high, especially in environments constrained by limited resources. Innovations in extracorporeal blood purification techniques have emerged as promising adjuncts in managing the dysregulated immune response characteristic of septic shock. These modalities aim to remove a spectrum of inflammatory mediators, such as cytokines and endotoxins, from the bloodstream, potentially restoring immunological equilibrium and improving patient outcomes. Yet, the comparative clinical efficacy of different blood purification strategies remains uncertain, fueling an intense debate within the critical care community.
A recent observational study conducted in a tertiary intensive care setting in Bosnia and Herzegovina sheds new light on this critical issue by directly comparing two prevalent extracorporeal blood purification systems: CytoSorbⓇ and oXirisⓇ. CytoSorbⓇ operates as a hemoadsorption cartridge integrated into standard CRRT circuits, selectively capturing inflammatory cytokines through adsorption. In contrast, oXirisⓇ utilizes a specialized membrane designed not only to provide renal support but also to facilitate the simultaneous removal of endotoxins and inflammatory mediators through adsorption and filtration mechanisms. This robust study encompassed 97 adult patients diagnosed with septic shock over a one-year period from 2023 to 2024. Researchers meticulously evaluated the impact of each device on patients’ hemodynamic recovery, focusing primarily on vasopressor-free days within the first 28 days post-treatment — a critical metric indicative of shock resolution and patient stabilization.
The findings reveal that both blood purification modalities induced notable hemodynamic improvements, as evidenced by reductions in serum lactate levels, decreased vasopressor dependency, and enhanced blood pressure stabilization following therapy. These objective physiological parameters underscore the potential of extracorporeal blood purification to transiently ameliorate the hemodynamic derangements associated with septic shock. However, despite these encouraging signs, the comparative analysis between CytoSorbⓇ and oXirisⓇ yielded no statistically significant differences in vasopressor-free days. Secondary outcome measurements, including durations of mechanical ventilation, lengths of intensive care unit (ICU) stay, and overall survival rates, similarly demonstrated equivalence between the two treatment arms, suggesting that both modalities may offer comparable clinical benefits in the acute management of septic shock.
The implications of these findings resonate deeply within critical care medicine. The authors emphasize that while extracorporeal blood purification undoubtedly influences key physiological variables, the intricate pathophysiology of sepsis involving persistent mediator production, cellular dysfunction, and dynamic redistribution of inflammatory agents could modulate—or even diminish—the long-term clinical impact of these interventions. Notably, patients subjected to CytoSorbⓇ therapy presented with higher baseline inflammatory markers, which may have confounded direct between-group comparisons and potentially obscured subtle efficacy distinctions. This underscores the complexity of patient heterogeneity in septic shock and highlights the nuanced challenge of tailoring extracorporeal therapies to individual patient profiles.
This study’s retrospective, single-center design inherently introduces certain limitations such as selection bias and potential residual confounding factors not accounted for in the analysis. Additionally, the limited sample size restricts the statistical power necessary to detect more modest but clinically relevant differences. Nevertheless, it represents one of the earliest direct assessments comparing two leading extracorporeal blood purification methods in a real-world clinical context, thus filling a vital knowledge gap. The equivalence observed therein provides a pragmatic perspective for intensivists contemplating these adjunctive therapies, suggesting flexibility in clinical decision-making based on availability, cost considerations, and patient-specific factors without compromising anticipated short-term hemodynamic results.
Looking ahead, the authors advocate for well-designed, larger-scale randomized controlled trials with multicenter collaboration to dissect further which patient subpopulations might derive the greatest benefit from blood purification and to optimize timing and modality selection. Such trials should incorporate comprehensive immunological and biochemical profiling to elucidate mechanistic pathways and refine patient stratification strategies. Integration of cutting-edge biomarker analytic techniques and real-time monitoring may prove instrumental in identifying therapeutic windows and maximizing clinical outcomes. As precision medicine advances, tailoring extracorporeal therapies will likely become integral to the nuanced management of septic shock.
Simultaneously, these findings reinforce a broader principle: while extracorporeal blood purification exerts beneficial short-term stabilizing effects, it is not a panacea for sepsis. Optimal sepsis care continues to rely on a multifaceted approach encompassing early antibiotic therapy, source control, hemodynamic support, and adjunctive strategies targeting underlying pathogen-host interactions. The persistent high mortality in septic shock reflects the complexity and heterogeneity of this syndrome rather than a failure of specific interventions, underscoring the importance of ongoing translational research and clinical innovation.
CytoSorbⓇ and oXirisⓇ, despite their differing technical mechanisms, both embody the evolution of critical care technology aimed at intercepting the deleterious inflammatory cascade. CytoSorbⓇ functions via a polymer bead adsorption system that binds middle molecular weight substances, whereas oXirisⓇ incorporates an AN69 membrane modified for endotoxin adsorption coupled with hemodialytic clearance. Understanding these subtle technological variations enhances clinicians’ ability to select devices aligning with individual pathophysiological demands, treatment goals, and resource availability, which is particularly pivotal in low-income healthcare settings.
In conclusion, this Bosnia and Herzegovina-based study delivers a timely and informative comparison of two pivotal extracorporeal blood purification strategies applied in septic shock management alongside continuous renal replacement therapy. Its results suggest that both CytoSorbⓇ and oXirisⓇ can improve short-term hemodynamics similarly without marked differences in vasopressor independence or survival. These insights provide a foundation for future investigations aiming to refine indications, optimize protocols, and explore integration with broader sepsis therapeutic frameworks. As the quest to unravel sepsis’s complexity persists, embracing evidence-based extracorporeal modalities offers hope for enhancing care quality and patient survival in this globally significant condition.
Subject of Research: People
Article Title: Impact of different extracorporeal blood purification strategies during continuous renal replacement therapy in septic shock patients
News Publication Date: 19-Feb-2026
References: DOI: 10.1016/j.jointm.2025.12.010
Image Credits: Prof. Pedja Kovacevic and Prof. Jihad Mallat from the University of Banja Luka, Bosnia and Herzegovina
Keywords
Septic shock, extracorporeal blood purification, CytoSorbⓇ, oXirisⓇ, continuous renal replacement therapy, cytokine removal, endotoxin adsorption, hemodynamic recovery, critical care, acute kidney injury, vasopressor-free days, intensive care unit
